In the majority of cases, prostate cancer remains localised and is therefore easily treatable. However, around 20 per cent of patients develop metastatic, incurable prostate cancer, which claims approximately 5,000 lives every year in Austria alone. Until now, there has been no satisfactory explanation as to why some patients develop metastases whilst others do not. A research team at MedUni Vienna has now discovered the significant changes in a protein that drive the growth and spread of prostate tumours. In their study, the researchers broke new ground by investigating the role of the protein KMT2C in prostate cancer. This protein acts as a regulator of key processes within the cells. If KMT2C loses this regulatory capacity due to mutations, the proliferation of the MYC oncogene is stimulated. This, in turn, drives cells to grow and spread the tumour at an increased rate. “Our study offers new insights into the previously poorly understood transition from locally confined to lethal, metastatic prostate cancer,” says study leader Lukas Kenner, highlighting the research findings. The new findings could also provide fresh impetus for the diagnosis and treatment of prostate cancer. For instance, the KMT2C mutation status could be determined via a blood test, thereby enabling early diagnosis and treatment. With the help of new drugs (MYC inhibitors), the increased cell division and associated metastasis could also be prevented. Furthermore: “As a high KMT2C mutation is characteristic of many types of cancer, such as breast, lung, bowel, bladder and even skin cancer, our study results have great potential for the research, diagnosis and treatment of malignant tumours in general,” says Kenner. Reference: MedUni Vienna, VetMedUni Vienna. KMT2C Methyltransferase Domain-regulated 1 INK4A expression suppresses prostate cancer metastasis, Molecular Cancer 2022; https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-022-01542-8
Prostate cancer: cause of metastasis discovered